Open Label Extension Protocol (Japan):Assess the Efficacy and Safety of Beremagene Geperpavec (B-VEC, previously KB103) for the Treatment of Japanese Patients with Dystrophic Epidermolysis Bullosa (DEB)
Latest Information Update: 11 Oct 2024
Price :
$35 *
At a glance
- Drugs Beremagene geperpavec (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Adverse reactions; Registrational
- Sponsors Krystal Biotech
- 26 Feb 2024 According to a Krystal Biotech media release, the Company anticipates filing a Japan New Drug Application in second half of 2024 enabling a potential authorization in 2025.
- 16 Aug 2023 Status changed from recruiting to completed.
- 12 Apr 2023 Planned number of patients changed from 30 to 45.